Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Egetis Therapeutics

8.06 SEK+0.88 %9.9. klo 18.29
Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.88 %
+13.84 %
+45.75 %
+56.20 %
+50.94 %
+50.94 %
+104.05 %
+27.31 %
-41.75 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
3.96B SEK
Turnover
6.48M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
6.11.
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release04.09.2026 klo 09.00

Emcitate® (tiratricol) Presentations at ETA and ESPE Congresses in September 2026

Egetis Therapeutics
Press release03.09.2026 klo 09.10

Egetis Therapeutics to Participate in Upcoming Investor Conferences in September

Egetis Therapeutics
Press release31.08.2026 klo 09.00

Tiratricol Granted Orphan Drug Designation for MCT8 Deficiency in Japan

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Egetis Therapeutics, Audiocast, Q2'26
Webcast21.08.2026 klo 15.00

Egetis Therapeutics, Audiocast, Q2'26

Egetis Therapeutics
Regulatory press release21.08.2026 klo 08.00

Egetis' Interim report Q2 2026

Egetis Therapeutics
Press release07.08.2026 klo 14.30

Invitation to Presentation of Egetis’ Q2 2026 Report on August 21, 2026

Egetis Therapeutics
Press release10.06.2026 klo 16.00

Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency

Egetis Therapeutics
Regulatory press release29.05.2026 klo 11.00

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Press release19.05.2026 klo 15.00

Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026

Egetis Therapeutics
Press release13.05.2026 klo 17.45

Exercise of options under employee stock option program and notification of insider trading

Egetis Therapeutics
Press release07.05.2026 klo 11.00

Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026

Egetis Therapeutics
Press release05.05.2026 klo 09.00

Egetis Announces Grant of Patent for MCT8 Deficiency Composition in the U.S.

Egetis Therapeutics
Press release30.04.2026 klo 13.30

Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026

Egetis Therapeutics
Regulatory press release30.04.2026 klo 10.05

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q1'26
Webcast29.04.2026 klo 11.00

Egetis Therapeutics, Audiocast, Q1'26

Egetis Therapeutics
Regulatory press release29.04.2026 klo 08.00

Interim report Q1 2026

Egetis Therapeutics
Press release24.04.2026 klo 12.00

Invitation to Presentation of Egetis’ First Quarter 2026 Report on April 29, 2026

Egetis Therapeutics
Regulatory press release21.04.2026 klo 23.57

Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million)

Egetis Therapeutics
Regulatory press release21.04.2026 klo 18.31

Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 350 million (approximately USD 38 million)

Egetis Therapeutics
Regulatory press release14.04.2026 klo 16.45

Bulletin from Egetis Therapeutics’ Annual General Meeting 2026

Egetis Therapeutics